What happens after menopause & nbsp;(WHAM): A prospective controlled study of depression and anxiety up to 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy

Martha Hickey; Katrina M Moss; Alison Brand; C David Wrede; Susan M Domchek; Bettina Meiser; Gita D Mishra; Hadine Joffe

Journal article

What happens after menopause & nbsp;(WHAM): A prospective controlled study of depression and anxiety up to 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy

Martha Hickey, Katrina M Moss, Alison Brand, C David Wrede, Susan M Domchek, Bettina Meiser, Gita D Mishra, Hadine Joffe

Gynecologic Oncology | ACADEMIC PRESS INC ELSEVIER SCIENCE | Published : 2021

DOI: 10.1016/j.ygyno.2021.02.001

Abstract

OBJECTIVE: Risk-reducing bilateral salpingo-oophorectomy (RRBSO) substantially reduces ovarian cancer risk in women with pathogenic gene variants and is generally recommended by age 34-45 years. Natural menopause is a vulnerable period for mood disturbance, but the risk of depression and anxiety in the first 12 months after RRBSO and potential modifying effect of hormone therapy are uncertain. METHODS: Prospective controlled observational study of 95 premenopausal women planning RRBSO and a Comparison group of 99 premenopausal women who retained their ovaries,- 95% of whom were at population level risk of ovarian cancer. Clinically significant symptoms of depression and anxiety were measured..

View full abstract

University of Melbourne Researchers

Martha Hickey Author Obstetrics and Gynaecology Royal Women's Hospital/Mercy

Related Projects (2)

PROMOTING AND ADVANCING MIDLIFE HEALTH IN WOMEN

Australia has an ageing population and women spend around one third of their lives after menopause. Optimising physical and emotional health..

IMPACT OF RISK-REDUCING BILATERAL SALPINGO-OOPHORECTOMY ON NON-CANCER OUTCOMES IN YOUNG HIGH-RISK WOMEN: A MULTICENTRE PROSPECTIVE STUDY

Growing numbers of Australian women are being identified at increased inherited risk of ovarian cancer. Removing the ovaries and Fallopian t..

Grants

Awarded by National Health and Medical Research Council of Australia (NHMRC)

Awarded by Susan G. Komen organization

Awarded by NHMRC

Funding Acknowledgements

This researchwas supported by Register4 through itsmembers' participation in research and/or provision of samples and information (register4.org.au).In Australia this study was supported by public funding provided by theNational Health andMedical Research Council of Australia (NHMRC; Grant #APP1048023), and by philanthropic funding provided by The RoyalWomen's Hospital (Melbourne, Australia), TheWomen's Foundation (Melbourne, Australia), Australia New Zealand Gynaecological Oncology Group (ANZGOG, Sydney, Australia) and theWestmead Hospital Familial Cancer Service (Sydney, Australia). In the USA this study was supported by philanthropic funding provided by the Basser Centre for BRCA and the Susan G. Komen organization (Grant #SAC150003). None of the funding agencies had a role in the design or conduct of the study, nor the collection, management, analyses or interpretation of the data, nor the preparation or approval of this manuscript.MH is supported by a NHMRC Practitioner Fellowship (ID number 1058935). SMD is supported by the Komen Foundation for the Cure. BM is supported by a NHMRC Senior Research Fellowship (ID number 1078523). GDM is supported by a NHMRC Principal Research Fellowship (ID number APP1121844).